About this trial

This multicenter study aims to establish the normal reference range of the Right Atrioventricular Coupling Index (RACI) in healthy Chinese adults using AI-based 3DE technology. It will also analyze the correlation between RACI and physiological parameters such as age, gender, and body surface area. Additionally, the study will explore the variation characteristics of RACI in patients with pulmonary hypertension, heart failure, tricuspid regurgitation, and atrial septal defect, and evaluate the clinical value of RACI in disease diagnosis, differential diagnosis, and risk stratification.

Eligibility criteria

Qualifiers

Of Han Chinese ethnicity

Aged 18-79 years

Normal blood pressure (< 140/90 mmHg)

Normal fasting blood glucose

Disqualifiers

Clinically significant cardiac valve regurgitation (≥ mild severity)

Respiratory diseases: acute or chronic respiratory disorders

Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.

Abnormal liver function (alanine transaminase > 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,640 Participants
are grouped into 5 trial groups

Locations

25
Chongqing Liangjiang New Area Hospital of Traditional Chinese Medicine ChongqingChongqing Municipality, China
Shenzhen People's Hospital ShenzhenGuangdong, China
Shijiazhuang People's Hospital ShijiazhuangHebei, China
The Third Affiliated Hospital of Hebei Medical University ShijiazhuangHebei, China

Sponsors and collaborators

First Hospital of China Medical University

Lead sponsor